HOTH News and Press, Hoth Therapeutics Inc. From 11/02/20

Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and Vaccine Hoth Therapeutics expects key proof-of-concept data in Q4 2020 / Q1 2021 for its COVID-19 products it is currently developing PR Newswire NEW YORK, Nov. 2, ...

DBV Technologies S.A. (DBVT) +80% as EMA approves Viaskin Peanut application.Endurance International Group Holdings (EIGI) +61% on announcing agreement to be acquired by Clearlake Capital Group L.P.AnPac Bio-Medical Science (ANPC) +30% as its Chinese company secu...

U.S. Patent and Trademark Office has granted Hoth Therapeutics ([[HOTH]] +3.3%) patent No. 10,793,525 related to 13-Cis-RAMBA retinamides optimized to target key signaling pathways implicated in a variety of cancers. The patent expires on October 5, 2036.The potential therapeut...

Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer Therapeutic The USPTO issued the first of its kind patent, which provides IP protection through October 2036 PR Newswire NEW YORK, Oct. 20, 2020 ...

Hoth Therapeutics (HOTH) completes the first phase of the research in examining the ability of HT-003 in blocking acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.Initial data from the phase reports t...

Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2) Initial data reports one of the most critical genes for acne pathophysiology, toll-like receptor 2 (TLR2), is significantly inhibited by HT-003 PR Newswire NEW YORK,...

Presentation Times and Weblinks Released for Over 150 Presenting Companies Day 1: Wednesday, September 23, 2020 ALL INSTITUTIONAL AND RETAIL INVESTORS ARE WELCOME NEW YORK, NY / ACCESSWIRE / September 22, 2020 / Sidoti & Company, LLC has released the presentation schedule,...

Hoth Therapeutics ([[HOTH]] -3.8%) has entered into a research agreement with the George Washington University, related to the development of an in vitro diagnostic device that allows immediate detection of SARS-CoV-2 via a mobile device.Nanohole array-based device utilizes plasmoni...

Hoth Therapeutics Enters into Sponsored Research Agreement for On-the-Go COVID-19 Testing Device Company will Partner with the George Washington University on R&D for their Licensed Smartphone-Based Direct Virus Sensing System PR Newswire NEW YORK, Sept. 21, 2020 ...

NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it has executed a manufacturing agreement for its vaccine portfolio with a global pharmaceutical contract development and manufacturing organization. The agreement partners Voltron with a multi-nati...